TSHA
Taysha Gene Therapies, Inc.
Biotechnology · Healthcare · United States
4.13
close · 2026-10-30
value
41
cheaper than peers41
quality
8
stronger fundamentals8
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -6.1% | 64 |
| earnings yield, 1 year ago | -8.7% | 60 |
| earnings yield, latest year | -8.2% | 58 |
| cash flow yield, latest year | -7.0% | 58 |
| cash flow yield, 2 years ago | -6.0% | 57 |
| price to book | 3.47× | 49 |
| cash flow yield, 3 years ago | -8.4% | 47 |
| earnings yield, 2 years ago | -23.2% | 42 |
| earnings yield, 3 years ago | -91.5% | 17 |
| price to sales | 180.12× | 10 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 32.3% | 37 |
| return on equity | -97.3% | 25 |
| operating margin | -1774.4% | 13 |
3 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$73.4M |
| employees | 99 |
| first trade | 2020-09-24 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.34 | -0.36 | -0.96 | -3.78 |
| free cash flow | -$93.8M | -$81.6M | -$80.4M | -$113.3M |
| net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M |
| revenue | $9.8M | $8.3M | $15.5M | $2.5M |
| unusual items | -$1.2M | -$4.8M | -$37.2M | -$36.4M |